|
Acorda is focused on identifying, developing and
commercializing novel pharmaceutical products that
address large and underserved CNS markets. The National
Multiple Sclerosis Society, or NMSS, currently estimates
that 400,000 people in the United States have multiple
sclerosis. People with MS may suffer impairments
in any number of neurological functions.
According to the National Spinal Cord Injury Statistical
Center, approximately 250,000 people in the United
States live with the long-term consequences of SCI
and approximately 11,000 new spinal cord injuries
occur each year, typically in young men. In addition
to the impact of paralysis on mobility and independence,
chronic SCI is often associated with several life-altering
conditions that vary depending on the individual
and the extent of injury.
Acorda's management
team has deep experience in all phases of drug
development and commercialization. Acorda has developed
an advisory network of leading scientists, clinicians,
and opinion
leaders in neurology. Depending
on their expertise, these advisors provide assistance
in trial design, conduct clinical trials, keep us
apprised of the latest scientific advances and help
us identify and evaluate business development opportunities.
The Company also has established in-house R&D
expertise and capabilities for the screening and
development of potential new CNS therapeutics.
Acorda is also committed to promoting the growth of the biotechnology industry in New York State, and is an active member and supporter of the New York Biotechnology Association (NYBA).
|
